Tidetron, a Chinese startup that uses synthetic biology to produce raw materials for industries from skincare to biopharmaceuticals, has closed an IDG Capital-led new funding round that brought its total fundraising size to over $100 million, the investor announced on Monday.
The new round is the fourth investment in the one-year-old startup, said IDG Capital. Its earlier investors include China-focused tech investment firm Unity Ventures, Legend Capital, a fund management platform of Chinese conglomerate Legend Holdings, and Beijing-based seed investor ZhenFund.
